Icotrokinra Long-term Results Affirm Promise of Targeted Oral Peptide With High Rates of Durable Skin Clearance and Favorable Safety Profile in Difficult-to-treat Scalp and Genital Psoriasis
October 24, 2025
October 24, 2025
RARITAN, New Jersey, Oct. 24 -- Johnson and Johnson Innovative Medicine issued the following news release:
* * *
Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
In areas of high impact, 72% of patients with scalp psoriasis and 85% with genital psoriasis treated with icotrokinra achieved site-specific clear or almost . . .
* * *
Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
In areas of high impact, 72% of patients with scalp psoriasis and 85% with genital psoriasis treated with icotrokinra achieved site-specific clear or almost . . .